Estrogen Receptor and Progesterone Receptor Evaluate the Malignancy of Papillary Thyroid Carcinoma: A Meta-Analysis And Systematic Review

2021 ◽  
Author(s):  
Guanyu Zhang ◽  
Xue Li ◽  
Wei Wang ◽  
Chaoyan Shen
Keyword(s):  
Systematic Review ◽  
Estrogen Receptor ◽  
Papillary Thyroid Carcinoma ◽  
Progesterone Receptor ◽  
Thyroid Carcinoma ◽  
Meta Analysis ◽  
Papillary Thyroid

scholarly journals Estrogen Receptor- and Progesterone Receptor-Positive Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: A Case Report

2013 ◽  
Vol 6 (1) ◽  
pp. 216-223 ◽  
Author(s):  
Yuichi Kinoshita ◽  
Kosho Takasu ◽  
Takashi Yuri ◽  
Kastuhiko Yoshizawa ◽  
Yuko Emoto ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Case Report ◽  
Papillary Thyroid Carcinoma ◽  
Progesterone Receptor ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Diffuse Sclerosing Variant

scholarly journals Hobnail variant of papillary thyroid carcinoma: a systematic review and meta-analysis

Endocrine ◽  
2020 ◽  
Author(s):  
Lane B. Donaldson ◽  
Flora Yan ◽  
Patrick F. Morgan ◽  
John M. Kaczmar ◽  
Jyotika K. Fernandes ◽  
...  
Keyword(s):  
Systematic Review ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Meta Analysis ◽  
Papillary Thyroid

scholarly journals Prophylactic Central Neck Dissection for cN1b Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

2022 ◽  
Vol 11 ◽  
Author(s):  
Xing-qiang Yan ◽  
Zhen-zhen Zhang ◽  
Wen-jie Yu ◽  
Zhao-sheng Ma ◽  
Min-long Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Meta Analysis ◽  
Central Neck Dissection ◽  
Central Neck ◽  
Papillary Thyroid ◽  
Prophylactic Central Neck Dissection ◽  
Neck Recurrence

BackgroundThe value of prophylactic central neck dissection (PCND) for papillary thyroid carcinoma (PTC) with clinically evident lateral cervical lymph node metastases (cN1b) remains unclear. Therefore, a systematic review and meta-analysis was conducted to assess the efficacy and safety of PCND.MethodsA comprehensive systematic search was conducted on PubMed, Web of Science, Cochrane library and Embase databases up to September 2021 to identify eligible studies. Controlled clinical trials assessing therapeutic effects and safety of PCND for cN1b PTC patients were included. The risk of bias for each cohort study was assessed using the Newcastle-Ottawa Scale (NOS). The primary outcomes were indexes related to the locoregional recurrence (LRR) and surgical complications. Review Manager software V5.4.0 was used for statistical analysis. A fixed effects model was adopted for the data without heterogeneity, otherwise a random effects model was used.ResultsWe included 4 retrospective cohort studies, which comprised 483 PTC patients. There was no statistically significant difference in the central neck recurrence (CNR) (10.2% vs. 3.8%, relative risk (RR) = 1.82; 95%CI 0.90–3.67; P = 0.09), lateral neck recurrence (LNR) (5.1% vs. 7.7%, RR = 0.47; 95% CI 0.13–1.74; P = 0.26), and overall recurrence (OR) (18.9% vs. 16.9%, RR = 0.77; 95%CI 0.34–1.76; P = 0.54), between LND + PCND group and LND group. Simultaneously, PCND increased the risk of permanent hypoparathyroidism (11.4% vs. 4.5%, RR = 2.70, 95%CI 1.05–6.94; P = 0.04) and overall complications (17.0% vs. 5.3%, RR = 3.28; 95%CI 1.37–7.86; P = 0.008).ConclusionsThis meta-analysis showed that PCND did not have any advantage in preventing LRR for cN1b PTC. Meanwhile, PCND may result in the increased rate of surgical complications. However, the current evidence is limited and more clinical trials are still needed to further clarify the true role of PCND.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, CRD42021281825.

Sign in / Sign up

Export Citation Format

Share Document